基础医学与临床 ›› 2019, Vol. 39 ›› Issue (1): 53-58.

• 研究论文 • 上一篇    下一篇

CYP19增强脱氢表雄酮抑制高脂诱导的兔主动脉及人脐静脉内皮细胞MMP-9的表达

周颖,赵敏,肖芳,李桃,李晓超   

  1. 秦皇岛市第一医院
  • 收稿日期:2018-02-25 修回日期:2018-05-30 出版日期:2019-01-05 发布日期:2018-12-28
  • 通讯作者: 赵敏 E-mail:496437510@qq.com
  • 基金资助:
    秦皇岛市科技支撑计划项目

CYP19 enhances inhibition of dehydroepiandrosterone on high fat-induced MMP-9 expression in rabbit aorta and HUVEC

  • Received:2018-02-25 Revised:2018-05-30 Online:2019-01-05 Published:2018-12-28
  • Contact: Min ZHAO E-mail:496437510@qq.com

摘要: 目的 探讨脱氢表雄酮(DHEA)抗动脉粥样硬化(AS)的作用及其机制。方法 将人脐静脉内皮细胞(HUVEC)分为对照组、ox-LDL组(30 mg/L ox-LDL)、DHEA(低和高浓度)干预组(30 mg/L ox-LDL + 0.1和1 μmol/L DHEA)、DHEA+全反式维甲酸(ATRA)干预组(30 mg/L ox-LDL + 1 μmol/L DHEA+ 0.01 μmol/L ATRA)及DHEA组(1 μmol/L)与上一行DHEA干预组重复?答:DHEA组是只加入DHEA作用组,DHEA干预组是同时加入ox-LDL和DHEA共同作用组,二者不重复。用real-time PCR和ELISA检测MMP-9 mRNA及蛋白的表达。通过脂质体介导的方法将pcDNA3.1-CYP19-GFP真核表达质粒(细胞色素P450芳香酶基因)及pcDNA3.1-GFP空质粒分别转染至人脐静脉内皮细胞(HUVEC),给予ox-LDL诱导及DHEA干预,用real-time PCR和ELISA检测转染细胞MMP-9 mRNA及蛋白的表达。将兔分为对照组、高脂组(口服1%胆固醇和3%猪油)、DHEA干预组(口服0.27% DHEA)、DHEA+ATRA干预组(口服0.6 mg/kg﹒d ATRA)及单DHEA组。用real-time PCR和免疫组织化学法检测兔主动脉MMP-9 mRNA及蛋白的表达。结果 ox-LDL组HUVEC MMP-9的表达较对照组明显升高(P<0.05);DHEA干预组呈浓度依赖性使MMP-9的表达明显回降(P<0.05)。高脂组兔主动脉MMP-9的表达较对照组明显升高(P<0.05);DHEA干预组能明显缓解高脂组的变化(P<0.05)。CYP19+ox-LDL+DHEA组较空质粒+ox-LDL+DHEA组MMP-9的表达显著降低(P<0.05)。结论 DHEA能抑制高脂诱导的兔主动脉及HUVEC MMP-9的表达,过表达细胞色素P450芳香酶基因(CYP19)能增强此作用。

关键词: 动脉粥样硬化, 脱氢表雄酮, 细胞色素P450芳香酶基因, 基质金属蛋白酶-9, 人脐静脉内皮细胞

Abstract: Objective To investigate the effect of DHEA on antiatherosclerosis and its mechanisms. Methods In vitro cultured HUVEC were divided into 6 groups: control group; ox-LDL group (30 mg/L ox-LDL); DHEA (low and high concentration) intervention group (30 mg/L ox-LDL + 0.1 and 1 μmol/L DHEA); DHEA+ATRA intervention group (30 mg/L ox-LDL + 1 μmol/L DHEA + 0.01 μmol/L ATRA); DHEA group (1 μmol/L). The expressions of HUVEC MMP-9 mRNA and protein were determined by RT-qPCR and ELISA respectively. The eukaryotic expression plasmid pcDNA3.1-CYP19-GFP (CYP19) and pcDNA3.1-GFP were transfected into HUVEC respectively. The transfected HUVEC were treated with ox-LDL and DHEA. The expressions of MMP-9 mRNA and protein of transfection groups were determined by RT-qPCR and ELISA. Rabbits were divided into 5 groups: control group; high lipid group (oral 1%cholesterol and 3%lard oil); DHEA intervention group (oral 0.27% DHEA); DHEA+ATRA intervention group (oral 0.6 mg/kg?d ATRA); DHEA group. The expressions of aortic MMP-9 mRNA and protein were determined by RT-qPCR and immunohistochemistry. Results The expression of MMP-9 in HUVEC in ox-LDL group was significantly increased as compared with control group (P<0.05); The expressions of MMP-9 in DHEA (low and high concentration) intervention groups were obviously decreased in a dose-dependent manner (P<0.05). The expression of aortic MMP-9 in high lipid group was significantly increased as compared with control group (P<0.05). Compared with high lipid group the expression of MMP-9 in DHEA intervention group was obviously decreased (P<0.05). The expression of MMP-9 in CYP19+ox-LDL+DHEA group was significantly decreased as compared with empty plasmid+ox-LDL+DHEA group (P<0.05). Conclusions DHEA inhibits high lipid induced MMP-9 expression in rabbit aorta and HUVEC. CYP19 over-expression can enhance the effect of DHEA.

Key words: artherosclerosis, dehydroepiandrosterone, CYP19, matrix metalloproteinase-9, human umbilical venous endothelial cells